Filter By
Clear all Advanced
I am/have/had
added new label for I am/have/had
more
I am looking for
added new label for I am looking for
more
Advanced Filters
Found 17 clinical trials
None
Ganciclovir to Prevent Reactivation of Cytomegalovirus in Patients With Acute Respiratory Failure and Sepsis

This is a phase 3 study designed to evaluate whether the administration of ganciclovir increases ventilator-free days in immunocompetent patients with sepsis associated acute respiratory failure

  • 0 views
  • 30 Jul, 2021
  • 20 locations
None
Systemic and Topical Antivirals for Control of Cytomegalovirus Anterior Uveitis: Treatment Outcomes

ganciclovir 2%, and placebo for the treatment of PCR-proven CMV anterior uveitis. This pilot study will provide valuable information concerning the treatment of CMV anterior uveitis with oral and topical

  • 17 views
  • 08 May, 2021
  • 1 location
None
An Open-Label Phase 2 Trial of Nanatinostat in Combination With Valganciclovir in Patients With Epstein-Barr Virus-Positive (EBV+) Relapsed/Refractory Lymphomas

A Phase 2 study to evaluate the efficacy of nanatinostat in combination with valganciclovir in patients with relapsed/refractory EBV-positive lymphomas

stem cell transplantation
measurable disease
  • 0 views
  • 26 Aug, 2021
  • 53 locations
None
Topical 2% Ganciclovir Eye Drop for CMV Anterior Uveitis / Endotheliitis

25 patients who are diagnosed with Cytomegalovirus (CMV) anterior segment infection, either uveitis or endotheliitis, will be started on 2% guttae ganciclovir, 1 drop 5 times a day for 6 weeks

dhpg
ganciclovir
  • 14 views
  • 26 Jan, 2021
  • 1 location
None
Certican (Everolimus) Against Cytomegalovirus Disease in Renal Transplant Patients

demonstrate efficacy of Certican® as add-on therapy against CMV disease in comparison to either valcyte® (valganciclovir) or cymevene® (ganciclovir) alone, evaluated by quantitative measurement of

dhpg
ganciclovir
valcyte
kidney transplant
valganciclovir
  • 0 views
  • 07 Nov, 2020
None
Phase I Study of CTL Anti-DP Infusion Post-hematopoietic Stem Cell Transplantation

clone in presence of a specific anti-viral drug named ganciclovir. We hypothesize that infusion of a third party suicide gene-transduced T cell clone directed against HLA-DPB1*401 might protect

hodgkin's disease
immunosuppressant
chronic leukemia
neutrophil count
graft versus host disease
  • 0 views
  • 06 Mar, 2021
  • 1 location
None
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer

The purpose of this study is to conduct a Phase I - II clinical trial to extend preclinical studies involving in situ HSV-tk + Valacyclovir gene therapy in combination with brachytherapy for recurrent prostate cancer. This will provide a novel therapeutic approach to prostate cancer and hopefully impact on the …

metastasis
external beam radiation therapy
brachytherapy
cancer treatment
recurrent prostate cancer
  • 17 views
  • 21 Jan, 2021
  • 1 location
None
Virotherapy and Natural History Study of KHSV-Associated Multricentric Castleman s Disease With Correlates of Disease Activity

This study will gain information about a rare disorder called KSHV-associated multicentric Castleman s disease (MCD). KSHV, a virus, causes several kinds of cancer, including some forms of MCD. KSHV stands for the Kaposi s sarcoma herpes virus, also called human herpes virus-8, or HHV-8. Researchers want to understand the …

doxorubicin
etoposide
nausea
cyclophosphamide
granulocyte colony stimulating factor
  • 57 views
  • 20 Oct, 2021
  • 1 location
None
CMV-CTL for the Treatment of CMV Infection After HSCT

Human cytomegalovirus (CMV) infection is a major cause of morbidity and mortality for recipients of allogeneic hematopoietic stem cell transplantation(HSCT). we propose to study the immunologic and virologic effects of donor derived CMV specific cytotoxic T lymphocyte (CMV-CTL) given to transplant recipients CMV antigen peptides will be used to induce …

foscarnet
dhpg
ganciclovir
stem cell transplantation
blood transfusion
  • 47 views
  • 25 Mar, 2021
  • 1 location
None
QuantiFERON-CMV Test in a Prediction for Colic Cytomegalovirus Reactivation During Ulcerative Colitis

CytoMegaloVirus (CMV) infection impairs evolution of Ulcerative Colitis (UC) leading to more severe and resistant to immunosuppressive therapies flare-up. CytoMegaloVirus (CMV) reactivation is assessed by the quantification of the CytoMegaloVirus (CMV) DeoxyriboNucleic Acid (DNA) load by real-time PCR (qPCR) in colonic biopsies; this assay is invasive and costly. The QuantiFERON-CytoMegaloVirus …

colitis
immunosuppressive agents
immunosuppression
  • 6 views
  • 26 Jan, 2021
  • 2 locations